Alnylam Notches Seventh FDA Approval as Livsayis Clears Myasthenia Gravis
Alnylam Pharmaceuticals has logged its seventh FDA-approved RNAi therapy, with Livsayis greenlit for anti-acetylcholine receptor positive generalized myasthenia gravis. Regeneron develops and sells the drug, so Alnylam collects a $25m approval milestone plus tiered royalties reaching 15% on global net sales.
- 2 sources report it: simplywall.st, ad-hoc-news.de.
- The source published it on Nov 21, 2026 at 11:09 AM.
Nothing open. Every check passed.
Livsayis became the seventh RNAi therapy built on Alnylam Pharmaceuticals' platform to win FDA approval, according to Simply Wall St. The drug is cleared for anti-acetylcholine receptor positive generalized myasthenia gravis, a neuromuscular autoimmune condition. Regeneron develops and commercializes the product, meaning Alnylam's role is financial rather than commercial.
That role comes with a US$25m approval milestone and tiered royalties of up to 15% on global net sales. The approval pushes Alnylam's RNAi platform past rare disease and into broader neurological territory, giving the company exposure to a condition well outside its transthyretin focus.
Simply Wall St notes the win adds another proof point for a pipeline that spans rare, specialty and prevalent diseases. It does not, however, directly loosen Alnylam's reliance on its TTR franchise or the pricing and access risks tied to it. Simply Wall St's narrative maps these catalysts to a $300 fair value for the stock.
The first real read on traction arrives in coming quarterly filings: Regeneron's reported Livsayis sales and the matching royalty line on Alnylam's books. Steady growth in global net sales there would show the drug is gaining ground in its approved myasthenia gravis population.
TopicsAlnylam Pharmaceuticals · ALNY · Livsayis · Regeneron · FDA · RNAi
Written by AI from verified reporting.
More stories
- Health & science sciencealert.com Caught by @ajayy30 1 viewKids With More Screen Time Scored Better on Teen Brain Tests, 8-Year Study Finds
- Health & science sciencealert.com Caught by @ajayy30 1 viewCockroaches Are Pollinating an Amazon Shrub After Dark, Study Finds
- Health & science breakingthenews.net 1 viewRussia presses Kazakhstan for answers on 'decimating virus'
- Health & science independent.co.uk Caught by @adihidayat 2 viewsWolbachia mosquitoes slash dengue infections by 69% in Brazil study

